{"success":true,"data":{"pressRelease":{"id":"75268","rtpr_id":"nGNXbYRBcj","ticker":"OBIO","exchange":"NASDAQ","all_tickers":["OBIO"],"title":"Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes","author":"Globe Newswire","published_at":"2026-06-29T12:00:00.601Z","article_body":"NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings,\nInc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a\nbiomedical company accelerating high-impact technologies to patients through\nrisk-reward sharing partnerships, announced today that it has joined the\nbroad-market Russell 3000(®) Index and the small-cap Russell 2000(®) Index\nat the conclusion of the 2026 Russell indexes reconstitution, effective after\nthe U.S. market close on June 26, 2026.\n\nThe Russell indexes reconstitution captures the 4,000 largest U.S. stocks as\nof April 30, ranking them by total market capitalization. Membership in the\nU.S. all-cap Russell 3000(®) Index, which remains in place until the next\nsemi-annual reconstitution, means automatic inclusion in small-cap Russell\n2000(®) Index as well as the appropriate growth and value style indexes.\nRussell indexes are part of FTSE Russell, a leading global index provider.\nFTSE Russell determines membership for its Russell indexes primarily by\nobjective, market-capitalization rankings, and style attributes.\n\nRussell indexes are widely used by investment managers and institutional\ninvestors for index funds and as benchmarks for active investment strategies.\nApproximately $12.2 trillion in assets are benchmarked against Russell's U.S.\nindexes.\n\nFor more information on the Russell 3000(®) Index and the Russell indexes\nreconstitution, go to the \"Russell Reconstitution\" section on the FTSE Russell\nwebsite here\n(https://www.globenewswire.com/Tracker?data=sjMacSnAQ_oJZe8zNAf82yifWo5u6foso6P-rz-0PGTdfTdC0dcUpDNYiRKJ4rSyk86NCkTqnsZ8H0pV5MuKanOCWIR2vfx_yRCmMgRmBv1qrsZgL3qrLid5kSlHSU9W).\n\nAbout Orchestra BioMed\nOrchestra BioMed is a biomedical innovation company accelerating high-impact\ntechnologies to patients through strategic collaborations with market-leading\nglobal medical device companies. The Company’s two flagship product\ncandidates - Atrioventricular Interval Modulation (AVIM) Therapy and\nVirtue(®) Sirolimus AngioInfusion(™) Balloon (Virtue SAB) - are currently\nundergoing pivotal clinical trials for their lead indications, each\nrepresenting multi-billion-dollar annual global market opportunities. AVIM\nTherapy is a bioelectronic treatment for hypertension, the leading risk factor\nfor death worldwide, and is designed to be delivered by a pacemaker and\nachieve immediate, substantial and sustained reductions in blood pressure in\npatients with hypertensive heart disease. The Company has a strategic\ncollaboration with Medtronic, one of the largest medical device companies in\nthe world and a global leader in cardiac pacing therapies, for the development\nand commercialization of AVIM Therapy for the treatment of uncontrolled\nhypertension in pacemaker-indicated patients. AVIM Therapy has FDA\nBreakthrough Device Designations for these patients, as well as an estimated\n7.7 million total patients in the U.S. with uncontrolled hypertension despite\nmedical therapy and increased cardiovascular risk. Virtue SAB is a highly\ndifferentiated, first-of-its-kind non-coated drug delivery angioplasty balloon\nsystem designed to deliver a large liquid dose of proprietary extended-release\nformulation of sirolimus, SirolimusEFR(™), for the treatment of\natherosclerotic artery disease, the leading cause of mortality worldwide.\nVirtue SAB has been granted Breakthrough Device Designation by the FDA for the\ntreatment of coronary in-stent restenosis, coronary small vessel disease and\nbelow-the-knee peripheral artery disease. For further information about\nOrchestra BioMed, please visit www.orchestrabiomed.com, and follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=yzgb6h06PuYb83_ZeK3qbS99w3d8cYwHy7eu10No9uQYXXcbmWQPYSSy3H1JivYO8GLkiQiFR5xyM3Cl7U4KfkJRT2SKNAZnlFuHeHqwBOYxo8MQCVs9QSQOhKUlz2FO).\n\nAbout FTSE Russell\nFTSE Russell is a global index leader that provides innovative benchmarking,\nanalytics, and data solutions for investors worldwide. FTSE Russell calculates\nthousands of indexes that measure and benchmark markets and asset classes in\nmore than 70 countries, covering 98% of the investable market globally.\n\nFTSE Russell index expertise and products are used extensively by\ninstitutional and retail investors globally. Approximately $12.2 trillion in\nassets are benchmarked against Russell's U.S. indexes. For over 30 years,\nleading asset owners, asset managers, ETF providers, and investment banks have\nchosen FTSE Russell indexes to benchmark their investment performance and\ncreate ETFs, structured products and index-based derivatives.\n\nA core set of universal principles guides FTSE Russell index design and\nmanagement: a transparent rules-based methodology is informed by independent\ncommittees of leading market participants. FTSE Russell is focused on applying\nthe highest industry standards in index design and governance and embraces the\nIOSCO Principles. FTSE Russell is also focused on index innovation and\ncustomer partnerships as it seeks to enhance the breadth, depth, and reach of\nits offering.\n\nFTSE Russell is wholly owned by London Stock Exchange Group.\n\nFor more information, visit www.ftserussell.com.\n\nReferences to information included on, or accessible through, websites and\nsocial media platforms do not constitute incorporation by reference of the\ninformation contained at or available through such websites or social media\nplatforms, and you should not consider such information to be part of this\npress release.\n\nInvestor Contact:\nSilas Newcomb\nOrchestra BioMed\nSnewcomb@orchestrabiomed.com\n\nMedia Contact:\nNina Premutico\nOrchestra BioMed\nnpremutico@orchestrabiomed.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/00697d05-bd34-4570-822b-f204caf21694)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbYRBcj","title":"Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes","author":"Globe Newswire","ticker":"OBIO","created":"2026-06-29T12:00:00.601Z","tickers":["OBIO"],"exchange":"NASDAQ","article_body":"NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings,\nInc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a\nbiomedical company accelerating high-impact technologies to patients through\nrisk-reward sharing partnerships, announced today that it has joined the\nbroad-market Russell 3000(®) Index and the small-cap Russell 2000(®) Index\nat the conclusion of the 2026 Russell indexes reconstitution, effective after\nthe U.S. market close on June 26, 2026.\n\nThe Russell indexes reconstitution captures the 4,000 largest U.S. stocks as\nof April 30, ranking them by total market capitalization. Membership in the\nU.S. all-cap Russell 3000(®) Index, which remains in place until the next\nsemi-annual reconstitution, means automatic inclusion in small-cap Russell\n2000(®) Index as well as the appropriate growth and value style indexes.\nRussell indexes are part of FTSE Russell, a leading global index provider.\nFTSE Russell determines membership for its Russell indexes primarily by\nobjective, market-capitalization rankings, and style attributes.\n\nRussell indexes are widely used by investment managers and institutional\ninvestors for index funds and as benchmarks for active investment strategies.\nApproximately $12.2 trillion in assets are benchmarked against Russell's U.S.\nindexes.\n\nFor more information on the Russell 3000(®) Index and the Russell indexes\nreconstitution, go to the \"Russell Reconstitution\" section on the FTSE Russell\nwebsite here\n(https://www.globenewswire.com/Tracker?data=sjMacSnAQ_oJZe8zNAf82yifWo5u6foso6P-rz-0PGTdfTdC0dcUpDNYiRKJ4rSyk86NCkTqnsZ8H0pV5MuKanOCWIR2vfx_yRCmMgRmBv1qrsZgL3qrLid5kSlHSU9W).\n\nAbout Orchestra BioMed\nOrchestra BioMed is a biomedical innovation company accelerating high-impact\ntechnologies to patients through strategic collaborations with market-leading\nglobal medical device companies. The Company’s two flagship product\ncandidates - Atrioventricular Interval Modulation (AVIM) Therapy and\nVirtue(®) Sirolimus AngioInfusion(™) Balloon (Virtue SAB) - are currently\nundergoing pivotal clinical trials for their lead indications, each\nrepresenting multi-billion-dollar annual global market opportunities. AVIM\nTherapy is a bioelectronic treatment for hypertension, the leading risk factor\nfor death worldwide, and is designed to be delivered by a pacemaker and\nachieve immediate, substantial and sustained reductions in blood pressure in\npatients with hypertensive heart disease. The Company has a strategic\ncollaboration with Medtronic, one of the largest medical device companies in\nthe world and a global leader in cardiac pacing therapies, for the development\nand commercialization of AVIM Therapy for the treatment of uncontrolled\nhypertension in pacemaker-indicated patients. AVIM Therapy has FDA\nBreakthrough Device Designations for these patients, as well as an estimated\n7.7 million total patients in the U.S. with uncontrolled hypertension despite\nmedical therapy and increased cardiovascular risk. Virtue SAB is a highly\ndifferentiated, first-of-its-kind non-coated drug delivery angioplasty balloon\nsystem designed to deliver a large liquid dose of proprietary extended-release\nformulation of sirolimus, SirolimusEFR(™), for the treatment of\natherosclerotic artery disease, the leading cause of mortality worldwide.\nVirtue SAB has been granted Breakthrough Device Designation by the FDA for the\ntreatment of coronary in-stent restenosis, coronary small vessel disease and\nbelow-the-knee peripheral artery disease. For further information about\nOrchestra BioMed, please visit www.orchestrabiomed.com, and follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=yzgb6h06PuYb83_ZeK3qbS99w3d8cYwHy7eu10No9uQYXXcbmWQPYSSy3H1JivYO8GLkiQiFR5xyM3Cl7U4KfkJRT2SKNAZnlFuHeHqwBOYxo8MQCVs9QSQOhKUlz2FO).\n\nAbout FTSE Russell\nFTSE Russell is a global index leader that provides innovative benchmarking,\nanalytics, and data solutions for investors worldwide. FTSE Russell calculates\nthousands of indexes that measure and benchmark markets and asset classes in\nmore than 70 countries, covering 98% of the investable market globally.\n\nFTSE Russell index expertise and products are used extensively by\ninstitutional and retail investors globally. Approximately $12.2 trillion in\nassets are benchmarked against Russell's U.S. indexes. For over 30 years,\nleading asset owners, asset managers, ETF providers, and investment banks have\nchosen FTSE Russell indexes to benchmark their investment performance and\ncreate ETFs, structured products and index-based derivatives.\n\nA core set of universal principles guides FTSE Russell index design and\nmanagement: a transparent rules-based methodology is informed by independent\ncommittees of leading market participants. FTSE Russell is focused on applying\nthe highest industry standards in index design and governance and embraces the\nIOSCO Principles. FTSE Russell is also focused on index innovation and\ncustomer partnerships as it seeks to enhance the breadth, depth, and reach of\nits offering.\n\nFTSE Russell is wholly owned by London Stock Exchange Group.\n\nFor more information, visit www.ftserussell.com.\n\nReferences to information included on, or accessible through, websites and\nsocial media platforms do not constitute incorporation by reference of the\ninformation contained at or available through such websites or social media\nplatforms, and you should not consider such information to be part of this\npress release.\n\nInvestor Contact:\nSilas Newcomb\nOrchestra BioMed\nSnewcomb@orchestrabiomed.com\n\nMedia Contact:\nNina Premutico\nOrchestra BioMed\nnpremutico@orchestrabiomed.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/00697d05-bd34-4570-822b-f204caf21694)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-29T12:00:00.719183386Z","server_sent_at_ms":1782734400719},"received_at":"2026-06-29T12:00:00.793Z","source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318888/0/en/Orchestra-BioMed-Joins-Russell-3000-and-Russell-2000-Indexes.html"},"analysis":{"id":"64622","press_release_id":"75268","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Orchestra BioMed announced that it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, effective after the market close on June 26, 2026.\n\nMembership in these indexes mandates inclusion for passive funds tracking the benchmarks, which cover approximately $12.2 trillion in assets, potentially increasing institutional demand for the company's shares.\n\nThe company highlighted its flagship product candidates, AVIM Therapy and Virtue SAB, noting that both are in pivotal clinical trials and have received FDA Breakthrough Device Designations.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Russell 2000 inclusion mandates passive fund flows, but does not alter business fundamentals."},"keyFigures":{"customDimensions":{"assets_benchmarked":"$12.2 trillion","index_stocks_count":4000,"target_patient_population_hypertension":7700000}},"quotedText":"","namedEntities":{"people":[{"name":"Silas Newcomb","role":"Investor Contact"},{"name":"Nina Premutico","role":"Media Contact"}],"products":["Atrioventricular Interval Modulation (AVIM) Therapy","Virtue Sirolimus AngioInfusion Balloon","SirolimusEFR"],"companies":[{"name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO"},{"name":"FTSE Russell","relationship":"index provider"},{"name":"Medtronic","relationship":"partner"},{"name":"London Stock Exchange Group","relationship":"parent of FTSE Russell"}],"dollarAmounts":[{"amount":"$12.2 trillion","context":"assets benchmarked against Russell's U.S. indexes"}]},"materialImpact":{"score":3,"reasoning":"Inclusion in the Russell 3000 and Russell 2000 indexes mandates passive fund ownership and increases institutional visibility, often driving near-term demand for shares, though it does not represent a fundamental change in business operations or financial results."},"tickerRelevance":{"others":[{"ticker":"MDT","relevance":"partner"}],"primary":"OBIO"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"index-inclusion","sectorWeight":"health-care"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Orchestra BioMed announced that it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, effective after the market close on June 26, 2026.\n\nMembership in these indexes mandates inclusion for passive funds tracking the benchmarks, which cover approximately $12.2 trillion in assets, potentially increasing institutional demand for the company's shares.\n\nThe company highlighted its flagship product candidates, AVIM Therapy and Virtue SAB, noting that both are in pivotal clinical trials and have received FDA Breakthrough Device Designations.","key_figures":{"customDimensions":{"assets_benchmarked":"$12.2 trillion","index_stocks_count":4000,"target_patient_population_hypertension":7700000}},"named_entities":{"people":[{"name":"Silas Newcomb","role":"Investor Contact"},{"name":"Nina Premutico","role":"Media Contact"}],"products":["Atrioventricular Interval Modulation (AVIM) Therapy","Virtue Sirolimus AngioInfusion Balloon","SirolimusEFR"],"companies":[{"name":"Orchestra BioMed Holdings, Inc.","ticker":"OBIO"},{"name":"FTSE Russell","relationship":"index provider"},{"name":"Medtronic","relationship":"partner"},{"name":"London Stock Exchange Group","relationship":"parent of FTSE Russell"}],"dollarAmounts":[{"amount":"$12.2 trillion","context":"assets benchmarked against Russell's U.S. indexes"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-29T12:14:28.225Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"index-inclusion","sectorWeight":"health-care"}},"durationMs":138630,"modelName":"george-droid-qwen-72b"}}